News & Updates
Filter by Specialty:
Simplified, tailored treatment for asthma improves patient outcomes
Asthma is a highly prevalent disease that can affect anybody regardless of age, race, and location. The overall burden of asthma remains severe. Despite the range of available therapies and well-established guidelines, there remains a significant unmet need in the management of asthma. [BMC Public Health 2012;12:860; Respir Res 2023;24:169; Eur Respir J 2014;43:343-373]
Simplified, tailored treatment for asthma improves patient outcomes
29 Nov 2023
COVID-19 infection ups CV risk in people living with HIV
People living with HIV (PLWH) who were diagnosed with COVID-19 had a 35-percent higher risk of a major cardiovascular (CV) event in the following year than PLWH without COVID in a Spanish study.
COVID-19 infection ups CV risk in people living with HIV
29 Nov 2023
BOREAS highlights dupilumab potential in COPD
In the phase III BOREAS trial, the monoclonal antibody dupilumab conferred multiple benefits for individuals with chronic obstructive pulmonary disease (COPD) and type 2 (T2) inflammation.
BOREAS highlights dupilumab potential in COPD
27 Nov 2023
Biweekly cabazitaxel plus G-CSF beneficial to certain older mCRPC patients
In the treatment of older patients with metastatic castration-resistant prostate cancer (mCRPC) who are considered unsuitable candidates for standard cabazitaxel (CBZ) regimens, treatment with CBZ at 16 mg/m2 (biweekly CBZ16) plus prophylactic granulocyte colony–stimulating factor (G-CSF) at each cycle helps reduce the risk of higher grade neutropenia and/or neutropenic complications while yielding similar clinical outcomes, according to the results of the phase III CABASTY trial.